Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Blackstone Life Sciences, Boston Scientific to co-fund development of ...

Licensing agreement New insurance product AI-generated analysis

🀝 Blackstone Life Sciences and Boston Scientific Corp. have entered a $455 million collaboration to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System.

🩺 The VITALYST system is a next-generation miniature heart pump designed to increase cardiac output and improve blood flow to vital organs during acute myocardial infarction cardiogenic shock.

πŸš€ This partnership represents the first time Blackstone Life Sciences and Boston Scientific will co-fund the development of a Boston Scientific product, highlighting a new strategic approach.

🎯 The initiative targets acute myocardial infarction cardiogenic shock (AMI-CS), addressing core unmet needs for critically ill patients with high mortality rates.

βš™οΈ The VITALYST system is engineered to improve efficacy, safety, and ease of use for physicians treating complex cardiovascular emergencies.

Bullish Signals
  • Blackstone Life Sciences has secured a $455 million collaboration with Boston Scientific Corp. to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System.
  • The partnership marks the first time Blackstone Life Sciences and Boston Scientific will jointly fund the development of a product, signaling strong confidence in the technology's potential.
  • The VITALYST system is designed to address significant unmet needs in treating acute myocardial infarction cardiogenic shock, a life-threatening condition with high mortality rates.
Full Analysis
Blackstone Life Sciences (BXLS) has announced a $455 million strategic collaboration with Boston Scientific Corp. to co-fund the development of the VITALYST Temporary Percutaneous Transvalvular Circulatory Support System program. This partnership marks the first instance where Blackstone Life Sciences and Boston Scientific will jointly fund the development of a product within Boston Scientific's portfolio. The VITALYST system is designed as a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It specifically targets acute myocardial infarction cardiogenic shock (AMI-CS), a life-threatening medical emergency where the heart fails to pump sufficient oxygenated blood to critical organs. The collaboration aims to address significant unmet needs for critically ill patients suffering from cardiogenic shock, which is associated with high mortality rates despite existing treatment advances. The VITALYST system focuses on improving efficacy, safety, and ease of use for physicians treating these complex cases, leveraging Boston Scientific's established expertise in cardiovascular technologies.